Shell Asset Management Co. lifted its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 123.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 30,238 shares of the medical equipment provider’s stock after purchasing an additional 16,683 shares during the quarter. Shell Asset Management Co.’s holdings in Zimmer Biomet were worth $3,861,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Lindbrook Capital LLC grew its holdings in shares of Zimmer Biomet by 207.6% during the 1st quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 137 shares during the period. Motco boosted its holdings in Zimmer Biomet by 86.2% in the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 100 shares during the period. Clean Yield Group purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $37,000. Doyle Wealth Management purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $41,000. Finally, Pinnacle Bank purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 88.49% of the company’s stock.

In other Zimmer Biomet news, Director Syed A. Jafry bought 1,925 shares of the business’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $125.52 per share, with a total value of $241,626.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.72% of the company’s stock.

A number of equities analysts have weighed in on the company. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a report on Friday, April 26th. Cantor Fitzgerald set a $135.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a report on Friday, April 26th. Needham & Company LLC upgraded Zimmer Biomet from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $146.00 to $155.00 in a report on Wednesday, April 24th. Barclays upped their price target on Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a report on Monday, April 15th. Finally, Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Saturday, April 13th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $130.19.

Shares of ZBH opened at $114.52 on Friday. Zimmer Biomet Holdings Inc has a 52-week low of $96.99 and a 52-week high of $134.55. The company has a market capitalization of $23.45 billion, a price-to-earnings ratio of 14.99, a price-to-earnings-growth ratio of 2.14 and a beta of 1.19. The company has a current ratio of 2.00, a quick ratio of 0.97 and a debt-to-equity ratio of 0.72.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.86 by $0.01. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The company had revenue of $1.98 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the company posted $1.91 EPS. Zimmer Biomet’s quarterly revenue was down 2.1% on a year-over-year basis. Sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date was Thursday, March 28th. Zimmer Biomet’s payout ratio is 12.57%.

COPYRIGHT VIOLATION NOTICE: “Shell Asset Management Co. Raises Stake in Zimmer Biomet Holdings Inc (ZBH)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/shell-asset-management-co-raises-stake-in-zimmer-biomet-holdings-inc-zbh/3022124.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: Municipal Bonds

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.